Profitability
This table compares Positron and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Positron | -300.00% | N/A | -89.57% |
Positron Competitors | -299.04% | -83.97% | -27.59% |
Valuation and Earnings
This table compares Positron and its competitors top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Positron | $740,000.00 | -$1.64 million | -12.13 |
Positron Competitors | $955.43 million | $79.50 million | 10.43 |
Positron’s competitors have higher revenue and earnings than Positron. Positron is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
Risk & Volatility
Positron has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Positron’s competitors have a beta of 0.88, meaning that their average share price is 12% less volatile than the S&P 500.
Summary
Positron competitors beat Positron on 6 of the 8 factors compared.
Positron Company Profile
Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.
Receive News & Ratings for Positron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Positron and related companies with MarketBeat.com's FREE daily email newsletter.